Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Abiraterone in high-risk prostate cancer
NCT05223582Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in prostate cancer (PCa), sponsored by Fudan University. Started May 2021; status: active, not recruiting.
02
Drugs
fluzoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05223582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223582.